Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, T-Cell, Peripheral × MLN 8237 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

10-propargyl-10-deazaaminopterin 7 Vincristine 5 Prednisone 5 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5 Cyclophosphamide 5 Doxorubicin 4 romidepsin 3 belinostat 3 Gemcitabine 3 liposomal doxorubicin 1 duvelisib 1 Vitamin B 12 1 MLN 8237 1 Folic Acid 1 Etoposide 1 E7777 fusion protein 1 Decitabine 1 Brentuximab Vedotin 1 Bendamustine Hydrochloride 1 BAEC protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Takeda

Phase 3 Completed

271 enrolled 25 charts

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡